Anticancer Drug Combinations, How Far We can Go Through?

Title:Anticancer Drug Combinations, How Far We can Go Through?

Volume: 17 Issue: 1

Author(s): Da-Yong Lu, En-Hong Chen, Hong-Ying Wu, Ting-Ren Lu, Bin Xu and Jian Ding

Affiliation:

Keywords: Drug combination, drug resistance, neoplasm metastasis, biotherapy, cancer stem cell, personalized cancer therapy.

Abstract: Many clinical cancer therapies are less effective by using one anticancer drug only due to refractory properties of cancer pathogenesis and drug resistance property in advanced cancer patients. A general consensus among clinicians is that anticancer drug cocktail might better control cancer progresses and metastasis than single drug therapeutics in clinical trials. Despite great popularity, the anticancer drug combination dogma has not been established. The complexity of drug combination dogma discovery is more than we can expect now. This article speculates possible routes we can undertake in this matter. The background knowledge of drug combination therapy presently practiced and possible future landscapes and drawbacks of cancer drug combinative therapies are highlighted.

Cite this article as:

Lu Da-Yong, Chen En-Hong, Wu Hong-Ying, Lu Ting-Ren, Xu Bin and Ding Jian, Anticancer Drug Combinations, How Far We can Go Through?, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (1) . https://dx.doi.org/10.2174/1871520616666160404112028